Seeking Alpha

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
Yahoo Finance

Avalyn Presents Multiple Posters on AP01 for Pulmonary Fibrosis, Including MIST Phase 2b Trial Design and ATLAS Phase 1b Study Post-hoc Analyses, at ERS 2024

CAMBRIDGE, Mass., Sept. 08, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening ...
Nasdaq

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Multiple Posters at the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress

MENLO PARK, Calif. and SINGAPORE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative ...
Mena FN

Avalyn Presents Multiple Posters On AP01 For Pulmonary Fibrosis, Including MIST Phase 2B Trial Design And ATLAS Phase 1B Study Post-Hoc Analyses, At ERS 2024

(MENAFN- GlobeNewsWire - Nasdaq) Trial Design Showcased for the MIST Study, a Recently Initiated Phase 2b Clinical Trial, Evaluating the Efficacy and Safety of AP01 (inhaled pirfenidone) Compared to ...